Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Esophageal Neoplasms 1Breast Neoplasms, Male 1Brain Neoplasms 1

Interventions

Radiosurgery 114Temozolomide 104Bevacizumab 71Radiotherapy 67Magnetic Resonance Spectroscopy 67Carboplatin 29pembrolizumab 28Irinotecan 26Surgical Procedures, Operative 25Radiation 23Nivolumab 23Etoposide 22Magnetic Resonance Imaging 21Ipilimumab 21Erlotinib Hydrochloride 21Cyclophosphamide 21Surveys and Questionnaires 19Aminolevulinic Acid 18Specimen Handling 16Pemetrexed 16Mental Status and Dementia Tests 16Cisplatin 16Carmustine 15Topotecan 14Trastuzumab 13Saline Solution 12Neuropsychological Tests 12Gefitinib 11Filgrastim 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Brain Neoplasms × ferumoxtran-10 × Clear all
NCT00659334 2022-12-21

Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation

OHSU Knight Cancer Institute

Phase 2 Terminated
116 enrolled 12 charts
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡